Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate

-- Telotristat etiprate, a Phase 3 compound for the treatment of carcinoid syndrome

-- Lexicon to potentially receive $145 million in upfront and milestone payments, plus royalties

Oct 22, 2014, 01:01 ET from Lexicon Pharmaceuticals, Inc.

$countyNameToPathMap.put("sp